AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Zynex Inc. (ZYXI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.41

-0.11 (-1.46%)

At close: Feb 20, 2025, 3:59 PM

7.41

0.00%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	7.21
Market Cap	235.98M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.14
PE Ratio (ttm)	52.93
Forward PE	n/a
Analyst	Buy

Ask	7.7
Volume	54,429
Avg. Volume (20D)	67,823
Open	7.55
Previous Close	7.52
Day's Range	7.33 - 7.55
52-Week Range	7.15 - 13.77
Beta	undefined

About ZYXI

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by fiel...

[Show more]

Industry Medical - Distribution

Sector Healthcare

IPO Date Feb 25, 2004

Employees 1,100

Stock Exchange NASDAQ

Ticker Symbol ZYXI

Website https://www.zynex.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for ZYXI stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 88.93% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Zynex Inc. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

-12.37%

Zynex shares are trading lower after the company r... Unlock content with Pro Subscription

News

3 weeks ago · proactiveinvestors.com

Zynex eyes FDA submission for NiCO oximeter as it expands portfolio of innovative medical devices

Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain monitoring. The company's flagship NexWave p...

2 months ago · proactiveinvestors.com

Zynex partners with VA to offer pain management solutions for veterans

Zynex Inc (NASDAQ:ZYXI) has announced a new partnership with Veterans Affairs Medical Centers (VAMCs) across the United States, a significant opportunity to expand the reach of its noninvasive medical...

2 months ago · proactiveinvestors.com

Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to em...

2 months ago · zacks.com

ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial

Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.

2 months ago · proactiveinvestors.com

Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter

Zynex Inc (NASDAQ:ZYXI) has announced its membership in the Collaborative Community of the Open Oximetry Project as an industry member. This initiative, led by the University of California, San Franci...

2 months ago · proactiveinvestors.com

Zynex leverages multi-modality NexWave device to transform pain management

Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on th...